These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 15337539)

  • 1. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
    Wahlgren T; Brandberg Y; Häggarth L; Hellström M; Nilsson S
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):51-9. PubMed ID: 15337539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life.
    Roeloffzen EM; Hinnen KA; Battermann JJ; Monninkhof EM; van Roermund JG; van Gellekom MP; Frank SJ; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1322-8. PubMed ID: 19939578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promising long-term health-related quality of life after high-dose-rate brachytherapy boost for localized prostate cancer.
    Wahlgren T; Nilsson S; Lennernäs B; Brandberg Y
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):662-70. PubMed ID: 17499452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life measurement in long-term survivors and outcome following radical radiotherapy for localized prostate cancer.
    Galalae RM; Loch T; Riemer B; Rzehak P; Küchler T; Kimmig B; Kovács G
    Strahlenther Onkol; 2004 Sep; 180(9):582-9. PubMed ID: 15378189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life up to six years after (125)I brachytherapy for early-stage prostate cancer.
    Roeloffzen EM; Lips IM; van Gellekom MP; van Roermund J; Frank SJ; Battermann JJ; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1054-60. PubMed ID: 20097486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
    Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
    Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA
    J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
    Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M
    Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study.
    Lips I; Dehnad H; Kruger AB; van Moorselaar J; van der Heide U; Battermann J; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):656-61. PubMed ID: 17512127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of high dose rate brachytherapy in combination with external beam radiotherapy on men's health-related quality of life and sexual function over a 2 year time span.
    Conaglen HM; de Jong D; Hartopeanu C; Conaglen JV; Tyrie LK
    Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):197-204. PubMed ID: 23183305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer.
    Hollenbeck BK; Wei JT; Sanda MG; Dunn RL; Sandler HM
    Urology; 2004 May; 63(5):946-50. PubMed ID: 15134986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-D conformal treatment of prostate cancer to 74 Gy vs. high-dose-rate brachytherapy boost: a cross-sectional quality-of-life survey.
    Vordermark D; Wulf J; Markert K; Baier K; Kölbl O; Beckmann G; Bratengeier K; Noe M; Schön G; Flentje M
    Acta Oncol; 2006; 45(6):708-16. PubMed ID: 16938814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life.
    Jo Y; Junichi H; Tomohiro F; Yoshinari I; Masato F
    BJU Int; 2005 Jul; 96(1):43-7. PubMed ID: 15963118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life 10 years after external beam radiotherapy or watchful waiting in patients with localized prostate cancer.
    Fransson P; Damber JE; Widmark A
    Scand J Urol Nephrol; 2009; 43(2):119-26. PubMed ID: 18985545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life of oral cancer patients after low-dose-rate interstitial brachytherapy.
    Yoshimura R; Shibuya H; Miura M; Watanabe H; Ayukawa F; Hayashi K; Toda K
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):772-8. PubMed ID: 18676096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localized prostate cancer: a prospective assessment of acute and late treatment toxicity.
    Wahlgren T; Nilsson S; Ryberg M; Lennernäs B; Brandberg Y
    Acta Oncol; 2005; 44(6):633-43. PubMed ID: 16165923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.